# Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

> **NCT00136604** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 617 (actual)

## Conditions studied

- Whole Cell Pertussis
- Haemophilus Influenzae Type b
- Hepatitis B
- Diphtheria
- Tetanus
- Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

## Interventions

- **BIOLOGICAL:** Tritanrix-HepB/Hib-MenAC
- **BIOLOGICAL:** Mencevax ACWY
- **BIOLOGICAL:** Tritanrix-HepB/Hiberix
- **BIOLOGICAL:** Meningitec

## Key facts

- **NCT ID:** NCT00136604
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-22
- **Primary completion:** 2006-04-23
- **Final completion:** 2006-04-23
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136604, "Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00136604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*